期刊文献+

HPLC法测定注射用福沙匹坦二甲葡胺中乙二胺四乙酸钙钠的含量 被引量:4

Determination of Calcium Disodium Edetate in Fosaprepitant Dimeglumine for Injection by HPLC
下载PDF
导出
摘要 目的:建立高效液相色谱法测定注射用福沙匹坦二甲葡胺中乙二胺四乙酸钙钠的含量。方法:采用Agilent Zorbax Eclipse XDB C18(250 mm×4.6 mm,5μm)色谱柱;以0.2%四丁基氢氧化铵溶液(用磷酸调节pH4.0)-乙腈(85∶15)为流动相,流速为1.0 ml·min-1,检测波长为254 nm,柱温为35℃,进样量为20μl。结果:乙二胺四乙酸钙钠在26.06~104.24μg· ml-1(r=0.9998)范围内呈现良好的线性关系;平均回收率为99.51%(RSD=0.25%,n=9)。结论:该方法简便、灵敏、准确、专属性强,重复性好,可作为注射用福沙匹坦二甲葡胺中乙二胺四乙酸钙钠含量测定的方法。 Objective:To establish an HPLC method for the determination of calcium disodium edetate in fosaprepitant dimeglu-mine for injection. Methods:The chromatographic column was Agilent Zorbax Eclipse XDB C18(250 mm ×4.6 mm,5μm). The mo-bile phase consisted of 0. 2% tetrabutylammonium hydroxide(adjusting pH to 4. 0 with phosphoric acid)-acetonitrile(85∶15). The flow rate was 1. 0 ml·min-1 . The detection wavelength was 254 nm. The chromatographic column temperature was 35℃. The injection volume was 20μl. Results:The calibration curve was linear within the range of 26. 06-104. 24μg·ml-1(r=0. 999 8) for calcium di-sodium edetate. The average recovery was 99. 51% (RSD=0. 25%, n=9). Conclusion: The method is simple, rapid, accurate, specific and reproducible, and can be used in the determination of calcium disodium edetate in fosaprepitant dimeglumine for injection.
出处 《中国药师》 CAS 2015年第5期711-713,共3页 China Pharmacist
基金 国家"重大新药创制"科技重大专项(编号:2010ZX09401-302)
关键词 高效液相色谱法 注射用福沙匹坦二甲葡胺 乙二胺四乙酸钙钠 HPLC Fosaprepitant dimeglumine for injection Calcium disodium edetate
  • 相关文献

参考文献5

二级参考文献13

共引文献112

同被引文献56

  • 1李琛,李迎丽,唐开红.离子色谱法测定罐头、酱菜等食品中的EDTA-2Na含量[J].中国卫生检验杂志,2005,15(10):1233-1234. 被引量:19
  • 2罗祎,赵永彪,李淑娟,陈冬东.反相高效液相色谱法测定食品中EDTA的含量[J].中国食品添加剂,2006,17(4):156-159. 被引量:21
  • 3金薇,杨永健,彭兴盛,陈桂良.雷贝拉唑对映体在α_1-酸性糖蛋白柱上的手性拆分[J].药物分析杂志,2006,26(12):1715-1717. 被引量:7
  • 4GB/T 27404-2008.实验室质量控制规范食品理化检测.
  • 5NCCN. Clinical Practice Guidelines in Oncology (Antiemesis) [ EB! OL]. http://www, nccn. org,2015-07-01/2015-12-7.
  • 6FDA. Emend ( fosaprepitant dimeglumine) for injection [ EB/OL ]. accessdata, fda. gov/drugsatfda docs/label/2014/ 022023sOl llbl. pdf. htm ,2014-08/2015-12-07.
  • 7Navari RM. Fosaprepitant (MK-0517) : a neurokinin-1 receptor an- tagonist for the prevention of chemotherapy-induced nausea and vomi- ting[ J ]. Expert Opin Investig Drugs ,2007,16 (12) : 1977-1985.
  • 8Colon-Gonzalez 17, Kraft WK. Pharmaeokinetie evaluation of fosaprep- itant Dimeglumine [ J]. Expert Opin Drug Metab Toxicol, 2010,6 (10) : 1277-1286.
  • 9Van Belle SJ, Cocquyt V. Fasaprepitant dimeglumine (MK-O517 or L-785,298), an intravenous neurokinin-1 antagonist for the preven- tion of chemotherapy induced nausea and vomiting [ J ]. Expert Opin Pharmacother,2008,9( 18 ) :3261-3270.
  • 10Saito H,Yoshizawa H,Yoshimori K,et al. Efficacy and safety of sin- gle-dose fosaprepitant in the prevention of chemotherapy-induced nau- sea and vomiting in patients receiving high-dose cisplatin: a multicen- tre, randomised, double-blind, placebo-controlled phase 3 trial [ J ]. Ann Onco1,2013,24 (4) : 1067-1073.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部